Literature DB >> 8487567

Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.

M Berruyer1, J Amiral, P Ffrench, J Belleville, O Bastien, J Clerc, A Kassir, S Estanove, M Dechavanne.   

Abstract

Brief case histories of three patients aged 58, 38, and 44 years are reported. All underwent cardiovascular operations. Subsequently hemostasis test abnormalities developed between the seventh and eighth postoperative days after exposure to bovine thrombin used with fibrin glue. These were characterized by an increased activated partial thromboplastin time (64 to 147 seconds), prothrombin time (19 to 24 seconds), bovine thrombin time (> 120 seconds) and a markedly reduced factor V level (< 10% in two patients and 16% in the third patient). A patient plasma dilution of 1 in 200 with a normal plasma pool was necessary to correct bovine thrombin time. No fast-acting or progressive inhibitor against factor V could be detected by coagulation tests, and fresh frozen plasma perfusion had no effect. Plasmapheresis was performed preventatively to avoid bleeding, and factor V levels stabilized at around 50% after two to four exchanges. Immunologic studies showed that the inhibitors were directed not only against bovine factors but also against human ones. Therefore factor V decrease could have been the result of rapid clearance from the circulation of complexes formed with a nonneutralizing inhibitor that is not detected by clotting tests. These antibodies were purified by standard methods and immunoaffinity. Fast immunization could be explained by a prior sensitization to bovine thrombin exposure during previous operations. It is suggested that bovine thrombin used with fibrin glue contains small amounts of factor V and may be responsible for these abnormalities. This is in agreement with previous literature reports. However, these described neutralizing factor V inhibitors, which were easily detected.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8487567

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors:  J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Authors:  J G Schoenecker; R K Johnson; A P Lesher; J D Day; S D Love; M R Hoffman; T L Ortel; W Parker; J H Lawson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  The long term immunological response of swine after two exposures to a salmon thrombin and fibrinogen hemostatic bandage.

Authors:  Stephen W Rothwell; Timothy Settle; Shannon Wallace; Jennifer Dorsey; David Simpson; James R Bowman; Paul Janmey; Evelyn Sawyer
Journal:  Biologicals       Date:  2010-08-11       Impact factor: 1.856

4.  Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

Authors:  B Tribl; P Knöbl; K Derfler; S Kapiotis; G Aspöck; U Jäger; W Hörl; K Lechner
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

5.  Thrombin use in surgery: an evidence-based review of its clinical use.

Authors:  Sung W Ham; Wesley K Lew; Fred A Weaver
Journal:  J Blood Med       Date:  2010-07-22

6.  Advantages of Fibrin Polymerization Method without the Use of Exogenous Thrombin for Vascular Tissue Engineering Applications.

Authors:  Vera G Matveeva; Evgenia A Senokosova; Viktoriia V Sevostianova; Mariam Yu Khanova; Tatiana V Glushkova; Tatiana N Akentieva; Larisa V Antonova; Leonid S Barbarash
Journal:  Biomedicines       Date:  2022-03-28

7.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

8.  Clinical use of topical thrombin as a surgical hemostat.

Authors:  Wesley K Lew; Fred A Weaver
Journal:  Biologics       Date:  2008-12

9.  Collagen fleece-bound fibrin sealant is not associated with an increased risk of thromboembolic events or major bleeding after its use for haemostasis in surgery: a prospective multicentre surveillance study.

Authors:  Mathias Birth; Joan Figueras; Stéphane Bernardini; Tine Troen; Klaus Günther; Darius Mirza; Frank Viborg Mortensen
Journal:  Patient Saf Surg       Date:  2009-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.